| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 12.5MM | -3% |
| Gross Profit | 4.9MM | -13% |
| Cost Of Revenue | 7.6MM | +5% |
| Operating Income | -3.1MM | +83% |
| Operating Expenses | 8MM | +9% |
| Net Income | -3MM | +69% |
| R&D | 1.7MM | +10% |
| G&A | 2.4MM | +24% |
| Marketing | 3.9MM | +1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
IRIDEX Corporation (NASDAQ:IRIX) Q4 2023 Earnings Call Transcript March 26, 2024 IRIDEX Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and thank you for standing by. Welcome to IRIDEX Q4 2023 Earnings Conference Call. At this time, all […]
Q4 2023 IRIDEX Corp Earnings Call
IRIDEX (IRIX) delivered earnings and revenue surprises of -260% and 16.39%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Advances strategic review to unlock shareholder valueMOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 30, 2023, and provided a business update. Fourth Quarter 2023 Results & Recent Highlights Gener
MOUNTAIN VIEW, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced it will release financial results for the fourth quarter and full year 2023 and provide an update on its strategic review process after the close of trading on Tuesday, March 26, 2024. The Company’s management team wi
MicroVision, Cutera and IRIDEX have been highlighted in this Industry Outlook article.
The Zacks Laser Systems and Components industry participants like MicroVision (MVIS), Cutera (CUTR) and IRIDEX Corporation (IRIX) gain from solid demand for emerging applications like autonomous driving, IoT, 5G and healthcare amid challenging macroeconomic conditions.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
The Advanced Short Pulse Laser SystemMOUNTAIN VIEW, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the grant of the European Patent EP 3009093, entitled "Laser System with Short Pulse Characteristics and its Methods of Use”. This groundbreaking patent further protects Iridex’s in
MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex’ Cyclo G6® Laser and the MicroPulse P3® Delivery Device. This partnership establishes a large-scale enrollment platform to adv